<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Luminex Corporation

    Luminex Corporation

    LuminexÂŽ Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietar...

    LuminexÂŽ Corporation (NASDAQ: LMNX) develops, ...

    Filing Type:    PU
    dna ID, Inc.

    dna ID, Inc.

    The DNA ID platform is a community marketplace for genomics research. The app allo...

    The DNA ID platform is a community marketplace ...

    Amount Raised:    $57,589.00
    Fundraising Status:    EC
    Filing Type:    CF
    Neurocarrus Inc

    Neurocarrus Inc

    Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...

    Neurocarrus is developing a breakthrough therap...

    Amount Raised:    $344,168.00
    Fundraising Status:    EC
    Filing Type:    CF
    La Jolla Pharmaceutical Company

    La Jolla Pharmaceutical Company

    La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company foc...

    La Jolla Pharmaceutical Company is a publicly t...

    Filing Type:    PU
    Provention Bio, Inc.

    Provention Bio, Inc.

    Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...

    Provention Bio, Inc. is a clinical-stage biopha...

    Filing Type:    PU
    Nabriva Therapeutics plc

    Nabriva Therapeutics plc

    Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...

    Nabriva Therapeutics is a commercial-stage biop...

    Filing Type:    PU
    Molecular Templates, Inc.

    Molecular Templates, Inc.

    Molecular Templates is focused on the discovery, development, and commercializatio...

    Molecular Templates is focused on the discovery...

    Filing Type:    PU
    Progenics Pharmaceuticals Inc.

    Progenics Pharmaceuticals Inc.

    Progenics develops innovative medicines and other technologies to target and treat...

    Progenics develops innovative medicines and oth...

    Filing Type:    PU
    Inovio Pharmaceuticals, Inc.

    Inovio Pharmaceuticals, Inc.

    Inovio is bringing IMMUNO-INGENUITY™ to life and is reshaping the future of trea...

    Inovio is bringing IMMUNO-INGENUITY™ to life ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.